Pixantrone Produces High Rates of Complete and Partial Remissions Even Among Aggressive NHL Patients With Extensive Prior Doxorubicin Treatment or Prior Rituximab Treatment

Panel Discussant Focuses on Longer Duration of Remission among Patients Achieving a Complete Remission with Pixantrone than Complete Remissions Achieved with Standard Chemotherapy ORLANDO, June 2 /PRNewswire-FirstCall/ -- Therapeutics, Inc. ("CTI") (Nasdaq and MTA: CTIC) announced today that ...

MitraClip(R) Therapy Data Shows Important Clinical Benefit in High Risk Patients With Functional Mitral Regurgitation at 12-Month Follow Up

EVEREST High-Risk Registry Data Shows Improved Symptomatic Status and Cardiac Function in Functional MR Patients Treated with the MitraClip(R) System ORLANDO, Fla., March 28 /PRNewswire/ -- Percutaneous mitral valve repair using the MitraClip(R) system in symptomatic high-risk surgical patien...

Mayo Clinic: Retired National Football League Linemen Have High Incidence of Sleep Apnea

ORLANDO, Fla., March 26 /PRNewswire-USNewswire/ -- Sleep disordered breathing, also known as sleep apnea, is highly prevalent among retired National Football League (NFL) players, and particularly in linemen, according to Mayo Clinic research. This study, involving 167 players, adds to the growi...

Diabetes Patients with High Triglycerides and Low HDL Cholesterol Get the Most Benefit From Fenofibrate Treatment: New Data From the FIELD Study

SYDNEY, Australia, Feb. 26 /PRNewswire/ -- Fenofibrate treatment reduces cardiovascular disease (CVD) risk (defined by total cardiovascular events: the composite of cardiovascular death, myocardial infarction, stroke, and coronary and carotid revascularization) in patients with type 2 diabetes...

Orthopaedic Injury: High Risk to Pregnant Women

New study finds even minor orthopaedic trauma can lead to medical problems for pregnant women and their unborn children LAS VEGAS, Feb. 25 /PRNewswire-USNewswire/ -- Pregnant women who experience orthopaedic trauma may minimize the risk of preterm birth and other prenatal complications if th...

Data Suggests New Antigen-Antibody Combo Test Useful for High Volume Public Health Screening

MONTREAL, Feb. 9 /PRNewswire-FirstCall/ -- A new HIV antigen-antibody combination assay, currently available in Europe, can be useful for high- volume screening to identify individuals with acute HIV infection, who would be missed by traditional HIV antibody tests, according to research presen...

Foreign Medical Devices are in High Demand in Russia

LAHTI, Finland, February 2 /PRNewswire/ -- The demand for medical devices has been increasing in recent years in Russia. Demand for imported high-tech medical devices is so high because local manufacturers concentrate mainly on inexpensive low-tech products. The medical devices and equipment i...

Arzerra(TM) (ofatumumab) Demonstrates High Response Rates in Patients With Fludarabine Refractory Chronic Lymphocytic Leukemia (CLL)

Data from a pivotal trial suggests that ofatumumab has activity in heavily pre-treated patients who have failed standard treatments PHILADELPHIA, Dec. 8 /PRNewswire-USNewswire/ -- GlaxoSmithKline (GSK) and Genmab A/S (OMX: GEN) announced today positive results from a pivotal trial pr...

Agendia Supports High Profile CME Symposium and Presents Compelling Data at the 2008 San Antonio Breast Cancer Symposium

HUNTINGTON BEACH, California and AMSTERDAM, December 8 /PRNewswire/ -- Agendia, a world leader in molecular cancer diagnostics, today announced that leading Agendia and the Netherlands Cancer Institute researchers will present data from multiple studies at the 2008 San Antonio Breast Cancer Sympos...

Boceprevir Phase II Study Showed High Rate of Sustained Response With 28- and 48-Week Regimens in Genotype 1 Treatment-Naive Hepatitis C Patients

Interim results of HCV SPRINT-1 study presented at AASLD annual meeting Pivotal Phase III studies ongoing in treatment naive patients and those who failed prior treatment SAN FRANCISCO, Nov. 1 /PRNewswire-FirstCall/ -- Schering-Plough Corporation (NYSE: SGP ) today reported that a planned...

Good Samaritan Hospital Launches High Risk Breast Cancer Program at Good Samaritan North Health Center

Advances in diagnostics and genetic testing give women answers about their risks DAYTON, Ohio, Oct. 1 /PRNewswire/ -- According to the U.S. Cancer Statistics Working Group (2007), an estimated 182,460 new cases of breast cancer will be diagnosed in American women...

First Published Study of New HPV Test for Developing Countries Shows High Accuracy in Predicting Cervical Disease

QIAGEN's careHPV test provides 'substantially more accurate' front-line screening VENLO, Netherlands, Sept. 21 /PRNewswire-FirstCall/ -- A new HPV test developed by QIAGEN specifically for use in regions of the world with scarce resources is "substantially" more a...

Novare Announces Successful Series of Single Port Lap Band Procedures With RealHand(R) High Dexterity Instruments

Dr. Julio Teixeira, Chief, Division of Minimally Invasive Surgery at St. Luke's-Roosevelt Hospital Center completes his 12th Single Port Lap-Band(R) Procedure; Bariatric patients now benefiting from 'hidden scar' procedure CUPERTINO, Calif., Sept. 2 /PRNewswire/ -- Novare Surgical Systems ann...

Study Shows Benefits of a High Omega-3 Diet in Older Adults

High Omega-3 Fat Intake Improves Insulin Sensitivity and Reduces Inflammatory Markers, But Does Not Alter Endocrine Responsiveness PHOENIX, Aug. 13 /PRNewswire-USNewswire/ -- A study conducted by Phoenix-based Kronos Longevity Research Institute (KLRI) found that a diet high in omega-3 fat i...

Top-Line Results of Boceprevir Phase II Study Showed High Rate of Sustained Response (SVR) in Genotype 1 Treatment-Naive Hepatitis C Patients

74 percent of patients achieved SVR 12 with 48-week boceprevir-based combination therapy High SVR 24 rate also reported for 28-week boceprevir arm KENILWORTH, N.J., Aug. 4 /PRNewswire-FirstCall/ -- Schering-Plough Corporation (NYSE: SGP ) today reported top-li...

Progen Terminates PATHWAY Trial & Confirms Focus on Potential High Value Molecules and M&A

BRISBANE, Australia, July 22 /PRNewswire-FirstCall/ -- Following a thorough review that concluded late yesterday, the Board of Progen Pharmaceuticals Limited (ASX: PGL; Nasdaq: PGLA) today announced that it had discontinued the PI-88 phase 3 study in liver cancer. Progen confirmed its strategi...

PAREXEL Data Reveal A Record High Number of Clinical Trials Initiated

BOSTON, June 23 /PRNewswire-FirstCall/ -- According to new data from PAREXEL International Corporation (Nasdaq: PRXL ), a leading global biopharmaceutical services organization, the number of new industry-sponsored clinical trial initiations, or starts, surged another 12 percent to a record h...

Sequential R-CHOP and Ibritumomab Tiuxetan (Zevalin(R)) Regimen Produces Impressive Survival Rates in High Risk Elderly Patients With Untreated Aggressive Diffuse Large B-cell Lymphoma

Oral presentation at international lymphoma conference shows investigational regimen resulted in 82 percent overall survival and 78 percent progression-free survival rates in patients receiving radioimmunotherapy Confirmatory phase III clinical trial is pr...

Phase 1/2 Trial of Motexafin Gadolinium Plus Antibody Targeted Radiation Therapy Demonstrates High Complete Response Rate in Patients With Non-Hodgkin's Lymphoma

SUNNYVALE, Calif., June 5 /PRNewswire-FirstCall/ -- Pharmacyclics, Inc. (Nasdaq: PCYC ) today announced final data from a Phase 1/2 study showing a 46 percent complete response rate in patients with multiply recurrent non-Hodgkin's lymphoma (NHL) who were treated with motexafin gadolinium (MG...

Kosan's Lead Hsp90 Inhibitor, Tanespimycin, Shows High Level of Activity in Trastuzumab Resistant/Refractory HER2-Positive Breast Cancer in a Phase 2 Trial

Data Presented at ASCO Show 26% Partial Response, 63% Clinical Benefit Incidence HAYWARD, Calif., June 3 /PRNewswire-FirstCall/ -- Kosan Biosciences Incorporated (Nasdaq: KOSN ) today announced that its lead Hsp90 inhibitor, tanespimycin, demonstrated a high lev...

Multiple Clinical Trials of VELCADE(R) (Bortezomib) for Injection Based Therapies Demonstrate High Complete Remission Rates in Patients with Newly Diagnosed Multiple Myeloma

CHICAGO, May 31 /PRNewswire/ -- Millennium Pharmaceuticals, The Takeda Oncology Company, today announced the presentation of results from three clinical trials of VELCADE based therapies that showed consistently high complete remission(1) (CR) rates in patients with newly diagnosed multiple my...

Genasense(R) Chemotherapy Program Yields High Response Rate in Patients with Stage 4 Melanoma

Related Clinical Study Shows Potential Utility of Short-Course High-Dose Therapy BERKELEY HEIGHTS, N.J., May 30 /PRNewswire-FirstCall/ -- Genta Incorporated (OTC Bulletin Board: GNTA) announced preliminary results that have shown a high objective response rate in...

New Data Support High Complete Remission Rates With VELCADE(R) (Bortezomib) for Injection Based Therapies in Patients With Newly Diagnosed Multiple Myeloma

- Five Oral Presentations at ASCO Annual Meeting Will Further Demonstrate the Strength of VELCADE Combinations in Front-line Multiple Myeloma - CAMBRIDGE, Mass., May 16 /PRNewswire/ -- Millennium Pharmaceuticals, The Takeda Oncology Company, today announced that new data from VELCADE clinica...

New Data Show High Frequency of Medical Claims for Gastrointestinal Events by Patients on Antiplatelet Therapy

Review of Insurance Claims Tracked Ulcers and Bleeding Among 368,000 Patients Prescribed Clopidogrel TORONTO, May 6 /PRNewswire/ -- A review of medical claims from more than 70 managed care plans showed that 6.2 percent of patients prescribed the antiplatelet medicine clop...

Lotrel, a Single-Pill Combination for Treating High Blood Pressure, Reduced Cardiovascular Events by 20% in High-Risk Patients

- ACCOMPLISH first study to compare two single-pill combinations of commonly used high blood pressure medicines in reduction of cardiovascular events - RAS inhibition with an ACEI was the foundation of the combination therapies in this study and exceptional b...

American Heart Association Journal Report: Reducing Kids' Salt Intake May Lower Soft Drink Consumption, Reducing Obesity, High Blood Pressure and Later Health Risks

DALLAS, Feb. 20 /PRNewswire-USNewswire/ --- Children who eat less salt drink fewer sugar-sweetened soft drinks and may significantly lower their risks for obesity, elevated blood pressure and later-in-life heart attack and stroke, researchers reported in the print and online issue of Hypertens...

Joslin Study Identifies Key Factor That Links Metabolic Syndrome; Finding May Help Millions at High Risk of Cardiovascular Disease

BOSTON, Feb. 5 /PRNewswire-USNewswire/ -- A new study led by researchers at Joslin Diabetes Center has identified insulin resistance in the liver as a key factor in the cause of metabolic syndrome and its associated atherosclerosis, disorders that put tens of millions of Americans at high risk...

Zevalin(R) Combined With High-Dose Chemotherapy and Autologous Stem-Cell Transplantation (ASCT) Produces High Overall Survival and Progression-Free Survival Rates in Patients With Relapsed Non-Hodgkin's Lymphoma

Results underscore promise of radioimmunotherapy in ASCT and warrant randomized trial SEATTLE, Jan. 17 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc. (CTI) (Nasdaq and MTAX: CTIC) announced today that results of a phase II clinical study, published in the Journa...

New Study Shows LEVITRA Successfully Treats Erectile Dysfunction (ED) in Men with Dyslipidemia, Including High Cholesterol

The first prospective trial specifically designed to evaluate erectile function in ED patients with dyslipidemia CHICAGO, Dec. 10 /PRNewswire-FirstCall/ -- Results of the first prospective trial specifically designed to evaluate erectile function in erectile dysfunction (ED) pat...

YouthAIDS, Levi's and BET's Rap It-Up Campaign Kick Off 2007 'Kick Me' Campaign to Raise HIV/AIDS Awareness at High Schools, Colleges and Universities Across the Country

Celebrity Spokespeople to Drive Young People to Do Something Radical and Simple to Fight the Spread of HIV/AIDS WASHINGTON, Nov. 20 /PRNewswire-USNewswire/ -- Look out for the Kick Me sign. It's back on the backs of college students around the nation. YouthAIDS, an action-based initiative im...

Isis Reports New Data for Mipomersen in Routine High Cholesterol Patients and Provides Cumulative Safety Summary

- Patients on stable doses of statins treated for 3 months with 200 mg/week mipomersen experienced 48% further reduction in LDL-cholesterol - Integrated Phase 1 & 2 safety update continues to support mipomersen's favorable safety profile - Isis hosting Analyst & Investo...

MedImmune Presents New Pharmaco-Economic Data at American Academy of Pediatrics Regarding Infants at High Risk for RSV

SAN FRANCISCO, Oct. 29 /PRNewswire/ -- MedImmune today announced results from a recent economic analysis of Synagis(R) (palivizumab), a monoclonal antibody (MAb) that is the standard of care for prevention of severe lower respiratory tract infection due to respiratory syncytial virus (RSV) in ...

Preliminary Results of Randomized Pilot Study Show Comparable Efficacy for OrbusNeich's Genous(TM) Bio-engineered R Stent(TM) and Boston Scientific's Taxus(R) Stent in Patients at High Risk of Restenosis

WASHINGTON, Oct. 22 /PRNewswire/ -- The preliminary results of the first- ever randomized study to compare OrbusNeich's pro-healing stent, the Genous Bio-engineered R stent, with Boston Scientific's Taxus drug-eluting stent in high risk of restenosis patients show comparable efficacy at 30-day...

Initial Results of Phase II Study with HCV Protease Inhibitor Boceprevir in Treatment-Naive Hepatitis C Patients Show a High Rate of Early Virologic Response

Top Line Results of Phase II Study in Previous Nonresponders also Reported KENILWORTH, N.J., Oct. 18 /PRNewswire-FirstCall/ -- Schering-Plough Corporation (NYSE: SGP ) today provided an update on the clinical development program for boceprevir, its investigational oral hepatitis C protease inh...

Large Blinded Clinical Study Achieves High Accuracy for the Diagnosis of Melanoma Using In Vivo Confocal Microscopy

- Lesions non-invasively imaged in 5 to 10 minutes - - Landmark Study Reported in Journal of Investigative Dermatology - ROCHESTER, N.Y., Sept. 18 /PRNewswire/ -- A landmark publication that appeared in the Journal of Investigative Dermatology reports the results of a large, two sit...

Trana Discovery and Southern Research Institute Announce the First RNA-RNA High Throughput Drug Screening Assay Platform for HIV Antivirals

Collaboration validates unique HIV assay system that identifies potential tRNA inhibitors CARY, N.C. and BIRMINGHAM, Ala., Sept. 17 /PRNewswire-USNewswire/ -- Trana Discovery, a drug discovery company, today announced the development of a high throughput screening (HT...

EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer

LYON, France, Aug. 17 /PRNewswire-FirstCall/ -- EDAP TMS S.A. (Nasdaq: EDAP), the global leader in High Intensity Focused Ultrasound (HIFU) treatment of prostate cancer, is currently conducting clinical investigations in France under an approved clinical trial combining the company's Ablatherm...

EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer

LYON, France, Aug. 17 /PRNewswire-FirstCall/ -- EDAP TMS S.A. (Nasdaq: EDAP), the global leader in High Intensity Focused Ultrasound (HIFU) treatment of prostate cancer, is currently conducting clinical investigations in France under an approved clinical trial combining the company's Ablatherm...

Tekturna, First New Type of High Blood Pressure Medicine in a Decade, Provides Additional Blood Pressure Reduction When Used With Diovan

* New study results show more patients receiving both Tekturna and Diovan reached target blood pressure goal compared to those taking either agent alone EAST HANOVER, N.J., March 26, 2007 /PRNewswire/ -- Results from a new study have shown patients taking two Novartis cardiovascular medicines -- t...

First-of-its-Kind National Report Reveals Estimated High Prevalence and Heavy Cost of Type 2 Diabetes Complications in America

In Response, Health Organizations Unite to Help Educate on Good Diabetes Management and How to Reduce the Risk of Other Serious Health Problems SEATTLE, April 10, 2007 /PRNewswire/ -- A first-of-its-kind report looking at the prevalence and cost of type 2 diabetes complications shows that an estim...